Potential conflict of interest: M.W. Russo does speaking and teaching for Gilead Sciences, Salix, Janssen, and Vertex; he receives research support from Merck, Vertex, and Salix. R.J. Fontana is a consultant for GlaxoSmithKline and receives research support from Vertex Pharmaceutical, Gilead and Bristol-Myers Squibb. N. Chalasani is a consultant for Aegerion, Merck, AbbVie, Salix, Lilly and Nimbus and receives research support from Cumberland, Gilead Sciences, Intercept Pharmaceuticals, and Galectin. H.L. Bonkovsky receives research support and is a consultant for Clinuval, Alnylam, Recordati, Vertex Pharmaceuticals, American Porphyria Foundation, and Iron Disorders Institute. The other authors declare no conflicts of interest to report.
Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network
Version of Record online: 13 MAY 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 2, pages 679–686, August 2014
How to Cite
Russo, M. W., Hoofnagle, J. H., Gu, J., Fontana, R. J., Barnhart, H., Kleiner, D. E., Chalasani, N. and Bonkovsky, H. L. (2014), Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology, 60: 679–686. doi: 10.1002/hep.27157
DILIN is supported by the National Institute of Diabetes and Digestive and Kidney Diseases under the following cooperative agreements: 1UO1DK065201, 1UO1DK065193, 1UO1DKO65184, 1UO1DK065211, 1UO1DK065238, and 1UO1DK06F5176. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute.
- Issue online: 22 JUL 2014
- Version of Record online: 13 MAY 2014
- Accepted manuscript online: 2 APR 2014 09:50AM EST
- Manuscript Accepted: 30 MAR 2014
- Manuscript Revised: 28 FEB 2014
- Manuscript Received: 27 DEC 2013
- 1www.drugtopics.com. Accessed on January 4, 2013.
- 10Drug Induced Liver Injury Network (DILIN) prospective study: rationale, design, and conduct. Drug Saf 2009;l32:55-68., , , , , , et al.
- 16www.livertox.nih.gov. Accessed on December 1, 2013.
- 22Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and rechallenge. Acta Neurol Taiwan 2007;16:163-167., , .